Participated · Equity · Apr 2026

Route 92 Medical develops neurovascular intervention technologies for acute ischemic stroke, notably the HiPoint Reperfusion System and its Monopoint approach to improve endovascular thrombectomy efficiency. The company completed the 250-patient SUMMIT MAX randomized trial, reporting strong safety and a high first pass effect rate. After submitting those results, the HiPoint Reperfusion System received FDA clearance in May 2025 for neurothrombectomy procedures. Route 92 has reported rapid growth in product adoption and an expanding commercial organization. With $50 million in new growth financing, the company intends to accelerate global commercial expansion, build clinical evidence for broader adoption, and continue investing in product innovation. Investors cited robust manufacturing capacity and a well-differentiated product portfolio as reasons for supporting the company’s next phase of growth.

Participated · Series F · Mar 2025

MicroTransponder is a global medical device company focused on research-based neuroscience solutions to restore sensory and motor function for people with neurological conditions. Its FDA-approved Vivistim Paired VNS System is clinically proven to generate improvement in upper limb function for chronic ischemic stroke survivors after six weeks of in-clinic occupational or physical therapy. Vivistim is an implanted device that a therapist pairs with vagus nerve stimulation (VNS) during high-repetition, goal-oriented therapy tasks to increase neuroplasticity. The company says Vivistim helps stroke survivors regain 2–3 times more upper extremity function. MicroTransponder intends to use the new funds to expand operations and its R&D efforts. The company is headquartered in Austin, Texas. MicroTransponder develops research-based neuroscience solutions and is focused on restoring function for people with neurological conditions that impair sensory and motor function. Its core product is the FDA-approved Vivistim Paired VNS System, which pairs vagus nerve stimulation with rehabilitation therapy to improve upper limb function for stroke survivors. The company says Vivistim generates more improvement in upper limb function than rehabilitation alone after six weeks of in-clinic therapy. MicroTransponder intends to use newly raised funds to support market development and commercialization of Vivistim. Leadership includes CEO Richard Foust and newly appointed COO Prashant Rawat, a named inventor on more than 85 patents and patent applications with over 25 years of medical device experience. Rawat’s role will focus on scaling operations to meet commercial demand, securing additional indications for Vivistim, and advancing development of the next-generation Paired VNS Therapy system. MicroTransponder is a Dallas, Texas-based medical device development company led by CEO Frank McEachern. The company develops and continues to expand neurostimulation programs to treat neurological diseases, including post-stroke motor rehabilitation and tinnitus. Its Vivistim® System is designed to treat stroke patients with upper limb deficit and consists of a small implanted battery and wires that connect to the vagus nerve in the neck. During rehabilitative therapy the device delivers a small amount of neurostimulation to the vagus nerve to strengthen neural pathways in the brain. MicroTransponder closed a $5.5M funding round in October 2015. The company intends to use the funds to commercialize its stroke and tinnitus therapies in Europe in 2016 and to complete additional clinical studies. MicroTransponder, Inc. is a Dallas, TX-based medical device company focused on vagus nerve stimulation therapies and wireless pain platforms. It partners with the University of Texas at Dallas to develop vagus nerve stimulation therapy for various neurological disorders. Initial therapeutic targets are stroke, tinnitus, and chronic pain, and its products include the Vivistim System for post-stroke upper-limb deficits and the Serenity® System for tinnitus. The company is led by CEO Frank McEachern. MicroTransponder intends to use new funding to complete three additional clinical trials for stroke and tinnitus and to continue development of its wireless pain platform. The company completed a $3.39M funding round and previously raised $9.6M in 2010. MicroTransponder is a Dallas, Texas-based medical device company developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications. Its initial product is the SAINT™ System for chronic pain. The company announced a $7M Series B financing and was awarded a $2.6M NINDS SBIR FastTrack U44 grant. The grant is a milestone-driven cooperative agreement to support pre-clinical validation of devices for neuropathic pain and manufacturing scale-up. The combined funding has allowed MicroTransponder to hire premier clinical and regulatory expertise and to prepare a series of clinical trials and regulatory filings for the SAINT System. Recent hires include Dr. Evan Rosenfeld as Chief Medical Officer and Vice President of Regulatory Affairs and Brent Tarver as Vice President of Clinical Affairs.

Participated · Series B · Aug 2024

Opkey provides an AI platform that continuously tests ERP systems, tracking integrations, updates, upgrades and user acceptance across enterprise applications. The platform covers packages including Oracle, Workday, Coupa, Veeva, Salesforce, SAP, Microsoft Dynamics, UKG and Trackwise. Opkey says it serves more than 200 large enterprise customers and has partnerships with system integrators such as KPMG LLC and PwC. The company was co-founded by CEO Pankaj Goel alongside Avinash Tiwari and Lalit Jain, all ERP industry veterans. Opkey positions its product to address testing and integration gaps that arise as cloud applications continuously update. The startup is based in Dublin, California and is focusing on automating ERP testing for large, digitally transforming organizations. Opkey provides a no-code test automation platform that instantly generates and transforms test cases for web, mobile, and ERP applications. The platform includes 30,000+ pre-built test cases across 14+ ERPs and 150+ technologies and is used by more than 250 enterprise clients. Founded in 2016 by Pankaj Goel, Avinash Tiwari, and Lalit Jain, the company automates process intelligence and testing to help enterprises keep pace with release schedules and ensure business continuity. Opkey recently released a new user interface it describes as the most user-friendly no-code interface on the market. The company plans to use new funding to expand product development, sales, and marketing, grow its U.S. presence, and make key hires such as a VP of Sales and Head of Marketing & Growth. It is headquartered in Dublin, California, with offices in New York, Pittsburgh, and India.

Participated · Series A · Jun 2023

Luminopia is a commercial-stage company pioneering a new class of treatments for neuro-visual disorders with its lead product, Luminopia, a software-based therapeutic for amblyopia delivered through a virtual reality headset. The FDA approved Luminopia via the De Novo pathway in October 2021, and a 510(k) clearance in November 2022 expanded the list of compatible headsets. The therapy uses dual-acting algorithms to modify TV shows and movies in real time (700+ hours of content) to promote weaker-eye usage and produced a 1.8-line mean improvement in visual acuity over three months in a Phase 3 pivotal trial. Luminopia is prescription-only, currently being prescribed at top eye institutes and private practices and is dispensed through a retail pharmacy. The company is preparing a full commercial rollout later this year and is an Innovation Partner of Boston Children’s Hospital, which holds equity. The recent financing is intended to support commercialization and scale adoption among eye-care professionals and patients aged 4–7 indicated for treatment. Luminopia develops a software-only, prescription digital therapeutic that runs on commercially available head‑mounted displays and uses proprietary algorithms to modify TV shows and movies in real time to promote weaker-eye usage. The lead product is FDA‑approved via the De Novo pathway (Oct 2021) and had a subsequent 510(k) clearance (Nov 2022) to expand compatible headsets; its Phase 3 pivotal trial demonstrated safety and efficacy and was published in Ophthalmology. The therapy is indicated to improve visual acuity in children aged 4–7 with amblyopia associated with anisometropia and/or mild strabismus and is intended for at‑home, prescription use alongside refractive correction. Luminopia provides 700+ hours of licensed content and delivers a binocular therapeutic effect, distinguishing it from monocular approaches like patching or atropine. The company plans a staged rollout to pediatric ophthalmologists starting this month, followed by a broader launch in the second half of 2023, with prescriptions distributed through an online retail pharmacy. The company recently completed an oversubscribed seed extension financing to support commercialization and broader market launch. Luminopia builds a prescription therapeutic that alters TV video in real time when viewed through a VR headset to promote usage of a weaker eye in children with amblyopia. The company has secured content deals with Sesame Workshop, Nickelodeon, DreamWorks and NBC to supply over 100 hours of modified programming. In a randomized controlled trial of 105 children, the treatment group improved by 1.8 lines on a standard eye chart versus 0.8 lines in the comparison group, with some children gaining two or more lines at 12 weeks. Adherence was high in the trial: children completed 88% of prescribed minutes and 94% of parents said they were likely or very likely to use the treatment instead of an eye patch. Earlier pilot data (including a small cohort of 10 children) showed roughly three-line improvements and informed the pivotal study. Luminopia submitted pivotal trial data to the FDA via the De Novo pathway last March and is anticipating a regulatory decision by the end of the year, with a potential product launch early next year if cleared. The company has about four employees and has raised roughly $12 million to date from investors including Sesame Ventures and angel backers such as Robert Langer and Jeffrey Dunn.

Participated · Series B · Apr 2022

Carlsmed develops the aprevo® personalized spine surgery platform, an AI-enabled system delivering patient-specific interbody fusion implants for lumbar fusion procedures. The company is commercializing aprevo for lumbar fusions and is developing a cervical fusion version planned to launch in 2025. Carlsmed’s implantable devices and software platforms are FDA cleared for lumbar spine fusion across anterior, lateral, and transforaminal approaches, and aprevo has received FDA Breakthrough Device designation for both lumbar and cervical devices. Management cites clinical publications showing aprevo patient-specific implants improve outcomes, and says its AI-enabled platform and business model enable rapid scaling of production to meet growing demand. Carlsmed’s mission is to improve outcomes and decrease healthcare costs for spine surgery, advancing the standard of care one patient at a time. Carlsmed produces aprevo®, an FDA‑cleared personalized spinal fusion device designed and manufactured for individual patients with spinal alignment correction built into the implant. The company leverages patient data and proprietary digital technologies, including machine learning and artificial intelligence, to create surgeon- and patient-specific implants. Carlsmed's stated mission is to improve outcomes and decrease the cost of healthcare for spine surgery by replacing mass-produced stock implants with bespoke devices. The company plans to use proceeds from its recent financing to ramp commercialization of aprevo® and scale adoption. Carlsmed closed an oversubscribed $30M Series B to support those commercialization efforts. Leadership additions tied to the round include Robert Mittendorff, MD, MBA joining the board and Widya Mulyasasmita joining as a board observer. Carlsmed develops the aprevo family of spine deformity correction devices, combining digital planning and personalized implants. Its platform uses machine learning and prior outcomes data to create optimized surgical plans and patient-specific aprevo implants. The company recently launched its Breakthrough aprevo devices and is focused on meeting surgeon and patient demand. Carlsmed's core product is a digital + surgical solution intended to enable superior correction of adult spinal deformities. The company says its mission is to help surgeons obtain better results at lower cost and help adults regain active lifestyles. Carlsmed is based in San Diego and has closed a $10M Series A to commercialize the aprevo devices. Carlsmed leverages machine learning and prior outcomes data to personalize treatment for complex adult spinal deformities. Its proprietary aprevo system creates surgical plans and patient-specific devices tailored to each individual's medical situation. The company positions the system to improve results while lowering treatment costs and helping adults regain active lifestyles. Carlsmed is incubating at EvoNexus and was named a Connect | San Diego Venture Group 2020 Cool Company. It recently closed an oversubscribed $2.5M seed round to accelerate the clinical launch of the aprevo system. The company also added Alexander Arrow as CFO and Shariq Hussain as CIO to build infrastructure and scale operations to meet clinical demand.